GLP-1 (glucagon-like peptide-1) receptor agonists are a major direction in current metabolic research. They are studied for their effects on insulin secretion, glucagon regulation, gastric emptying and satiety signaling. Popular research peptides in this group include semaglutide, liraglutide, exenatide, tirzepatide and retatrutide. All products discussed on this page are supplied for laboratory research use only.

Choosing the right peptide for a research program depends on receptor profile, half-life, dosing convenience, formulation, and the consistency of the supplied batch. The table below summarizes commonly studied members of this group at a high level; confirm the exact specification, CAS number and COA for the batch you receive.

Comparison of Major GLP-1 Related Peptides

ProductReceptor ProfileHalf-lifeAdministrationResearch Focus
SemaglutideGLP-1 receptor agonistAbout 7 daysSubcutaneous injectionGlucose metabolism, weight regulation research
LiraglutideGLP-1 receptor agonistAbout 13 hoursSubcutaneous injectionGlucose metabolism, appetite signaling research
ExenatideGLP-1 receptor agonistAbout 2.4 hoursSubcutaneous injectionShort-acting GLP-1 signaling studies
TirzepatideGIP / GLP-1 dual agonistAbout 5 daysSubcutaneous injectionCombined incretin pathway research
RetatrutideGLP-1 / GIP / glucagon triple agonistResearch-stageSubcutaneous injectionMulti-receptor metabolic pathway research

Mechanism of Action

GLP-1 receptor agonists bind to GLP-1 receptors and act through several connected pathways: they promote glucose-dependent insulin secretion, suppress glucagon release, slow gastric emptying, and increase the feeling of satiety. Dual and triple agonists extend this profile by engaging additional incretin or glucagon receptors, which is why they are studied alongside single-receptor agonists.

Because these pathways are glucose-dependent, researchers typically evaluate dose response, formulation stability and receptor selectivity under controlled laboratory conditions rather than relying on half-life alone.

Half-life and Dosing Considerations

Half-life determines how often a compound needs to be administered in a study. Short-acting peptides such as exenatide require more frequent dosing, while longer-acting compounds such as semaglutide and tirzepatide support less frequent schedules. Reconstitution concentration, storage temperature and aliquoting also affect how long a prepared solution remains usable.

What to Check Before Sourcing

These peptides are intended for in vitro and preclinical laboratory research only. They are not for human, veterinary, food or cosmetic use.